截至XNUMX月底的一周，生物技术股上涨。 疫苗新闻流引发的反弹也推高了大盘，这是13日。本周始于辉瑞公司的积极消息。 （NYSE：PFE）及其德国合作伙伴BioNTech SE – ADR（NASDAQ：BNTX）报告了他们共同研发的针对COVID-3冠状病毒的mRNA疫苗的中期19期阳性数据。竞争对手疫苗开发商Moderna Inc（NASDAQ： MRNA）在达到其首次中期分析的法定病例数时也产生了乐观.300 Prime Therapeutics Inc（NASDAQ：FPRX）在一周内上涨了XNUMX％以上，其上涨主要是由于其研究阶段性中期研究取得积极成果与此同时，Supernus Pharmaceuticals Inc（纳斯达克股票代码：SUPN）在FDA拒绝其ADHD药物后受到压力，收益消息继续流传，但本周在IPO方面保持沉默。 在本周内举行了多次会议，这为生物制药公司提供了展示他们所研究产品的新数据的机会。以下是XNUMX月开始的一周的主要推动因素。 13，会议*美国眼科学会（AAO），2020年虚拟会议：XNUMX月。 13-15日*美国肝脏疾病研究协会（AASLD），肝脏会议，数字体验：XNUMX月。 13-16日*古根海姆医疗保健讲座，创意论坛，第二届年度神经/免疫学日：2月。 16 * Stifel 2020虚拟医疗会议：XNUMX月。 16-18日* Jefferies虚拟伦敦医疗保健会议：XNUMX月。 17-19日* Wolfe研究虚拟医疗保健会议：XNUMX月。 18-19 *结缔组织肿瘤学会或CTOS，虚拟年度会议：XNUMX月。 18-21 * SVB Leerink肿瘤学日：XNUMX月。 19 * 2020神经肿瘤学会或SNO，虚拟会议：XNUMX月。 19-21PDUFA日期FDA决定对精神分裂症和双相性I型疾病的ALKS 3831进行Alkermes Plc（NASDAQ：ALKS）NDA裁决。 （星期天）周日，阿达米斯药物公司（NASDAQ：ADMP）Zimhi（阿片类药物过量的研究治疗药物）的命运将由FDA决定.Mylan NV（NASDAQ：MYL）等待FDA对其ANDA的认可富马酸二甲酯，一种由Biogen Inc（NASDAQ：BIIB）生产的仿制药，用于治疗复发性多发性硬化症。 FDA将PDUFA的日期定为XNUMX月。 Bristol-Myers Squibb Co's（NYSE：BMY）的BLA for liso-cel作为至少两次先前治疗后复发或难治性大B细胞淋巴瘤患者的治疗选择。 （星期一）艾格生物制药公司（纳斯达克股票代码：EIGR）在XNUMX月与FDA等待决定性的时刻。 关于Lonfarnib在早衰和早衰型laminopathy方面的NDA评估为20。 临床读数/数据演示AAO会议演示谱系细胞治疗公司（纽约证券交易所：LCTX）：正在进行的1 / 2a阶段主要研究结果更新了其领先的候选药物OpRegen在与干龄相关的黄斑变性中的研究。 (Sunday); the company has also scheduled a call with key opinion leaders Tuesday, 4 pm ET, to discuss the data.AASLD Presentations Albireo Pharma Inc (NASDAQ: ALBO): new data from a Phase 3 study of odevixibat in progressive familial intrahepatic cholestasis (Sunday)Inventiva ADR Representing Ord Shs (NASDAQ: IVA): new data from the NATIVE Phase 2b clinical trial evaluating lanifibranor for NASH, focusing on the efficacy of lanifibranor in type-2 diabetic patients and its positive effect on key plasma biomarkers (Sunday)Akero Therapeutics Inc (NASDAQ: AKRO): additional data analysis from the Phase 2a BALANCED study of efruxifermin in non-alcoholic steatohepatitis (Sunday)Dicerna Pharmaceuticals Inc (NASDAQ: DRNA): Updated Phase 1 data for RG6346 in HBV infection (Monday)CymaBay Therapeutics Inc (NASDAQ: CBAY): a late-breaking presentation highlighting results from the ENHANCE Phase 3 study of seladelpar in patients with primary biliary cholangitis (Monday)Related Link: 7 Stocks That Could Benefit From Pfizer’s COVID-19 Vaccine That Requires Cold Chain Storage SNO Meeting Presentations VBI Vaccines Inc (NASDAQ: VBIV): data from Part B of the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (Thursday)Kintara Therapeutics Inc (NASDAQ: KTRA): update on Phase 2 studies of VAL-083 in MGMT-unmethylated Recurrent Glioblastoma Multiforme (Thursday)Plus Therapeutics Inc (NASDAQ: PSTV): new interim data from the ongoing NIH-sponsored ReSPECT Phase 1 clinical trial evaluating its lead investigational asset, Rhenium NanoLiposome in patients with recurrent glioblastoma (Thursday)CTOS Presentations Karyopharm Therapeutics Inc (NASDAQ: KPTI): data from the Phase 3 portion of the SEAL study of Xpovio in advanced dedifferentiated liposarcomaCogent Biosciences Inc (NASDAQ: COGT): final clinical data from its Phase 1/2 study of PLX9486 in gastrointestinal stromal tumorsStandalone Data Readouts Avrobio Inc (NASDAQ: AVRO) will announce at its Virtual R&D Day scheduled for Tuesday additional details on its new Hunter syndrome program, while also sharing new data on its three clinical programs, including initial clinical data from its Gaucher disease program.Pfizer and BioNTech expect safety data milestone to be achieved in the third week of November and plan for emergency use authorization shortly after.Moderna could release interim Phase 3 readout for its coronavirus vaccine candidate, given it has said it has reached the mandated number of cases for analysis.Earnings Monday Vascular Biogenics Ltd (NASDAQ: VBLT) (before the market open) Jaguar Health Inc (NASDAQ: JAGX) (before the market open) Celsion Corporation (NASDAQ: CLSN) (before the market open)Tuesday Trinity Biotech plc (NASDAQ: TRIB) (before the market open) PAVmed Inc (NASDAQ: PAVM)Wednesday Edap Tms SA (NASDAQ: EDAP) (after the close)Thursday Precipio Inc (NASDAQ: PRPO) (after the close)Friday Burning Rock Biotech Ltd (NASDAQ: BNR) (before the market open)IPOs San Diego, California-based Maravai Lifsciences Holding, Inc. 该公司计划在首次公开募股中出售其50万股普通股，发行价格在24-27美元之间。 该公司提供的关键产品可以促进药物疗法，诊断学，新型疫苗的开发以及对人类疾病的支持研究，该公司表示其股票将在纳斯达克上市，股票代码为MRVI.Sotera Health Company是一家灭菌实验室。测试和咨询服务公司已向SEC提交了招股说明书，以发行其46.6万股普通股，发行价格在20美元至23美元之间。 这家总部位于俄亥俄州Broadview Heights的公司已申请将其股票在纳斯达克上市，股票代码为SHC。IPO安静期到期Foghorn Therapeutics Inc. （纳斯达克股票代码：FHTX）查看本辛加的更多信息*单击此处以查看本辛加的期权交易* Moderna首次读取临时报告的COVID-19案号：下一步是什么？ *辉瑞冠状病毒疫苗数据对Moderna（C）2020 Benzinga.com的意义。 Benzinga不提供投资建议。
,